Search ARM

Advancing Gene, Cell, & Tissue-Based Therapies

ARM Annual Report & Sector Year in Review: 2019

The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.

ARM Annual Report & Sector Year in Review: 2019

The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.

Back to Publications

Global Landscape

987+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total 2019 Global Financings

Total Global Financing

$9.8 Billion

2nd Highest Year on Record

Gene & Gene-modified
Cell Therapy

$7.6 Billion

2nd Highest Year on Record

Cell Therapy

$5.1 Billion

4th Highest Year on Record

Tissue Engineering

$442 Million

3rd Highest Year on Record

Total Global Financings by Type

1,066

regenerative medicine
clinical trials ongoing worldwide
as of the end of 2019

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

EOY 2019

Gene Therapy

Gene-Modified Cell Therapy
& Cell-Based IO

Cell Therapy

Tissue Engineering

Clinical Trials by Indication: 2019

Report Infographics

View European Data View Full Report